TNF and inflammatory bowel disease: Overall, the prevalence of ocular inflammation remained low in large cohort studies because, first, a large part of patients with IBD received systemic corticosteroid and/or antitumor necrosis factor (TNF)-α agents, which may decrease ocular inflammation.